Docetexal plus S-1 Versus Oxaliplatin plus S-1 for First-Line Treatment of Patients with Advanced Gastric Cancer: A Retrospective Study

Wang, Mei; Wu, Meihong; Wang, Wei; Wang, Qingshui; Wang, Yajie

doi:10.1159/000358162

Cited by 4 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the simplified de Gramont regimen [9], which adopts two-day 5-FU infusion with leucovorin, is worthy of investigation on AGC. Docetaxel, a semi-synthetic taxoid, also showed high response rate and prolonged survival in both monotherapy and combination therapy [10, 11]. In addition, the combination of docetaxel and 5-FU analogue could exert potential synergistic actions against human gastric cancer [12]; however, most studies have administered docetaxel every 3 weeks with a high dose intensity that resulted in poor tolerability.…”

Section: Introductionmentioning

confidence: 99%

Bi-weekly docetaxel and 5-fluorouracil: an effective and feasible treatment for advanced gastric cancer with poor performance status

Tan

Chen

et al. 2014

Gastroenterology Report

View full text Add to dashboard Cite

Background: The survival benefits from cytotoxic chemotherapy have been demonstrated in advanced gastric cancer (AGC). A large proportion of AGC patients initially present poor performance status (PS); however, most of the clinical evidence comes from trials on patients with good PS. A better-designed regimen is greatly needed for AGC patients with poor PS.Objective: To evaluate the efficacy and safety of a modified combination regimen with docetaxel plus 5-fluorouracil (5-FU) every two weeks as first-line treatment in AGC patients with poor PS.Methods: From September 2011 to December 2013, 12 patients diagnosed with AGC with Eastern Cooperative Oncology Group (ECOG) PS scores of 3 or 4 were included in this study. All the patients received docetaxel 60 mg/m2 on Day 1, 5-FU 400 mg/m2 intravenous (i.v.) bolus on Day 1, and a 46-hour continuous i.v. infusion of 5-FU 2400 mg/m2 every two weeks, until disease progressed or patients experienced unacceptable toxicity or declined treatment. Detailed clinical, pathologic and survival data were all recorded.Results: Eleven out of 12 patients were assessable for responses, whereas nine cases (75%) achieved partial response, one (8.3%) achieved stabilized disease, and one (8.3%) had progressive disease. The median progression-free survival was 6.5 months (95% CI: 4.8–8.2). The median overall survival was 12.0 months (95% CI: 9.0–15.0). The most common Grade 3/4 toxicities were anemia in seven patients (58.3%). No patient experienced febrile neutropenia.Conclusion: The novel modification of bi-weekly docetaxel and 5-FU is a promising treatment option for AGC with poor PS, showing great efficacy and acceptable toxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Bi-weekly docetaxel and 5-fluorouracil: an effective and feasible treatment for advanced gastric cancer with poor performance status

Tan

Chen

et al. 2014

Gastroenterology Report

View full text Add to dashboard Cite

show abstract

Progress and remaining challenges in comprehensive gastric cancer treatment

et al. 2022

View full text Add to dashboard Cite

Gastric cancer (GC) is the fifth most common cancer among all cancer fields and currently the third most common cause of cancer-related deaths both in men and women worldwide. Additionally, the incidence and mortality of GC significantly varies due to different eating habits and environmental and genetic factors in different areas. Remarkably, with the development of techniques and surgical equipment along with newly emerging drugs and therapeutics, the 5-year survival for GC patients has increased and the death rate has decreased. In this perspective, based on current therapies in GC field around the world, we present a systematic discussion about the state of advanced clinical treatments including surgical resection, systemic chemotherapy, targeted therapy, radiotherapy and enhanced recovery after surgery. Although challenges remain which require further study and investigation, in this review, we mainly focus on the promising clinical treatment strategies in GC to date.

show abstract

Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis

Shi

Gao

Song

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Taxanes are chemotherapeutic agents commonly used to treat several cancers. However, the effects of taxanes on advanced gastric cancer (AGC) are still not clear, especially when used as a first-line treatment. This systematic review and meta-analysis aims to investigate the efficacy and safety of taxanes as a first-line treatment of AGC. The quality of our included studies was assessed using the Cochrane risk of bias tool for RCTs and NOS scale for nRCTs, and the data of the included studies was of satisfactory quality to analyze. The outcomes included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and toxicity. Taxanes significantly improved OS (HR = 0.84, 95% CI 0.76–0.92, P = 0.0004) and had a slight effect on ORR (RR = 1.23, 95% CI 1.00–1.51, P = 0.05). However, taxanes may also increase the risks of neutropenia and leucopenia, similar to effects observed in other conventional chemotherapeutic treatments such as oxaliplatin and epirubicin. Therefore, patient characteristics including concomitant diseases, physical condition, and prior therapies should be considered before selecting taxane-based treatments for AGC.

show abstract

Docetexal plus S-1 Versus Oxaliplatin plus S-1 for First-Line Treatment of Patients with Advanced Gastric Cancer: A Retrospective Study

Cited by 4 publications

References 19 publications

Bi-weekly docetaxel and 5-fluorouracil: an effective and feasible treatment for advanced gastric cancer with poor performance status

Bi-weekly docetaxel and 5-fluorouracil: an effective and feasible treatment for advanced gastric cancer with poor performance status

Progress and remaining challenges in comprehensive gastric cancer treatment

Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis

Contact Info

Product

Resources

About